EXECUTIVE INTERVIEWS

  • Can David Hung Lead Axovant To Alzheimer’s Success?
    Can David Hung Lead Axovant To Alzheimer’s Success?

    Why would David Hung, M.D., a veteran pharma executive, forgo retirement (after a big acquisition payday), join Axovant Sciences, and then invest $10 million of his own money into the small company? Our chief editor sat down with him to get the answers to those questions and more.

  • Can We Make Innovative Medicines Affordable?
    Can We Make Innovative Medicines Affordable?

    “As the price of pharmaceuticals continues to rise, we are seeing greater resistance from [U.S.] patients being willing to pay,” says Dr. Steven Miller. The SVP and chief medical officer at Express Scripts is giving his opening remarks during the Our Common Goal: Ensuring Access and Affordability of Innovative Medicines session at the 2017 BIO International Convention in San Diego. Miller pulls no punches with his fellow biopharmaceutical executive panelists, setting the tone that today’s discussion on drug pricing will not be a “hugfest.”

  • Prometic: New Tech Harvests Orphan Treatments
    Prometic: New Tech Harvests Orphan Treatments

    Always stick with your original goals, even when you reap another, off-the-scale success. Like many biopharma companies, Prometic invented a novel technology platform, initially to make new medicines available to unserved populations.

  • Behind The Scenes Of Allergan’s Social Contract
    Behind The Scenes Of Allergan’s Social Contract

    The story behind Allergan’s bold decision to formalize its social contract with patients told to our Chief Editor by Brent Saunders, Allergan’s chairman, president, and CEO.

  • P3s: How To Get The Good …Without The Bad
    P3s: How To Get The Good …Without The Bad

    At this year’s BIO International Convention in San Diego (June 19 – 22), I moderated a session, Navigating A Clear Path To Public-Private Partnerships, and we talked about the good, the bad, and the ugly of P3s. After a brief introduction, the first question was posed, resulting in the following edited dialogue.

  • Cytokinetics: Keeping Its Sights On Independence
    Cytokinetics: Keeping Its Sights On Independence

    Can a biopharma company have a soul? If so, the soul should be one that endures. “The biology is the soul of our company,” says Robert Blum, president and CEO of Cytokinetics. “We have pioneered an area of biology — muscle activation — proven to offer a compelling pharmacology.

More Executive Interviews

BEYOND THE PRINTED PAGE

  • Daniel Skovronsky – From Grad Student, To CEO, To Big Pharma

    Daniel Skovronsky, M.D., Ph.D., is the SVP of clinical and product development at Eli Lilly and Company. But prior to taking on this role, he held the title of CEO of Avid Radiopharmaceuticals — a company he founded in Philadelphia while still a graduate student at the University of Pennsylvania. This article explores some of the differences between this executives past and present roles, and is a good prequel to the upcoming article that explores how he went about building a $300 million company.

  • Does The Biopharmaceutical Industry Need To Broaden Its Horizons?

    When I interviewed Axovant Sciences CEO David Hung, one of the questions posed was sparked by our discussion of his experience at Pro-Duct Health and his invention of a microcatheter for early detection of ductal breast cancer in women. As he explained his medical device invention, Hung commented, “I don’t want to be just medicines, or just devices, or anything like that.”

  • What Might Be The Best Predictor Of Future Performance At Axovant Sciences?

    Chief Editor Rob Wright recently conducted an in-person interview with David Hung, formerly of Medivation and current  CEO of Axovant Sciences. Though many may credit the FDA’s approval of Medivation’s Xtandi (enzalutamide) as being the primary driver behind Hung’s rise, Wright argues that there are a number of other predictors that should be evaluated when anticipating future success.

More From Beyond The Printed Page

LIFE SCIENCE LEADER BLOGS

  • Why <em>Every</em> Company Needs A Bio Strategy
    Why Every Company Needs A Bio Strategy

    Today we stand on the precipice overlooking a new frontier — the century of biology, and businesses of all kinds need to be prepared to not only embrace what is coming, but have a strategy for how to leverage biology for the betterment of their businesses and the good of the planet.

  • What Is BIO Hoping To See Among Session Submissions For 2018?
    What Is BIO Hoping To See Among Session Submissions For 2018?

    Life Science Leader Chief Editor Rob Wright is cochairing the 2018 BIO educational program planning committee. In this blog he talks about why this was the earliest the planning committee has ever met and what you can do to submit interesting and novel session proposals that will get the attention of the committee.

More From Life Science Leader Blogs

@LIFESCILEADER1